Evidence map›Paper›PMID 29206770›Full record

ArticleMenopause (New York, N.Y.)2018

The cross-sectional association between chemerin and bone health in peri/pre and postmenopausal women: results from the EPIC-Potsdam study.

Juliane Menzel, Ronald Biemann, Krasimira Aleksandrova, Matthias B Schulze, Heiner Boeing, Berend Isermann, Cornelia Weikert

Open access · hybridAbstract read
In one paragraph

Article in Menopause (New York, N.Y.), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.2field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 1 country.

Juliane MenzelDepartment of Molecular Epidemiology, German Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal, Germany.
Ronald BiemannInstitute for Clinical Chemistry and Pathobiochemistry, Otto-von-Guericke University Magdeburg, Magdeburg, Germany.
Krasimira AleksandrovaNutrition, Immunity and Metabolism Start-up Lab, Department of Epidemiology, German Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal, Germany.
Matthias B SchulzeDepartment of Molecular Epidemiology, German Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal, Germany.
Heiner BoeingDepartment of Epidemiology, German Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal, Germany.
Berend IsermannInstitute for Clinical Chemistry and Pathobiochemistry, Otto-von-Guericke University Magdeburg, Magdeburg, Germany.
Cornelia WeikertGerman Federal Institute for Risk Assessment, Department of Food Safety, Berlin, Germany.
German Institute of Human Nutrition · DEOtto-von-Guericke University Magdeburg · DEDeutsches Diabetes-Zentrum e.V. · DEFederal Institute for Risk Assessment · DEGerman Center for Diabetes Research · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveRecent in vitro data suggested that the novel adipokine chemerin may influence bone health. However, only limited evidence of the relationship between chemerin and bone health in humans is available. Therefore, this study aimed to investigate the association between chemerin and broadband ultrasound attenuation (BUA) in peri/premenopausal and postmenopausal women.

methodsData from the German population-based European Prospective Investigation into Cancer and Nutrition-Potsdam cohort comprising 404 peri/premenopausal and 279 postmenopausal women were analyzed. Multivariable-adjusted analysis of covariance including age, body mass index, waist circumference, smoking status, education, physical activity, alcohol consumption, and hormone use was used to investigate potential relationships between the adipokine and BUA levels in peri/premenopausal and postmenopausal women, respectively.

resultsThe concentrations of chemerin were lower in peri/premenopausal women (median 118.0 ng/mL, interquartile range [IQR] 99.2-135.0), compared with postmenopausal women (median 140.0 ng/mL, IQR 121.0-167.0). In peri/premenopausal women chemerin was inversely associated with BUA levels; after multivariable adjustment, a 10% increase in the chemerin concentration was significantly associated with 0.83 dB/MHz lower BUA levels (P = 0.0006). In postmenopausal women chemerin was not related to BUA levels (P = 0.8).

conclusionThe present study provides evidence for an inverse association between chemerin and BUA in peri/premenopausal women. Therefore, the study suggests that high chemerin concentrations may minimize peak bone mass and thereby may promote age-related bone loss. Further studies are needed to investigate the role of chemerin in bone homeostasis in peri/premenopausal and postmenopausal women.

Indexed as

AdultBone DensityChemokinesCohort StudiesFemaleHumansIntercellular Signaling Peptides and ProteinsMiddle AgedOsteoporosisPerimenopausePostmenopausePremenopauseProspective StudiesChemokinesIntercellular Signaling Peptides and ProteinsRARRES2 protein, human

Identifiers

PMID29206770
PMCPMC5908253
OpenAlexW2772530880

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.